This episode features Paige Twenter, Assistant Editor at Becker's Healthcare. Here, she discusses recent developments in the healthcare sector. Twenter highlights new research on the safety and risks associated with GLP-1 drugs, particularly Ozempic, and its potential benefits for chronic kidney disease. She also examines legislative changes affecting the 340B drug pricing program and their implications for hospitals and drug manufacturers, emphasizing the growing tension between these stakeholders.